Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Seifert

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Oncoimmunology|January 27, 2022
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)Nadine Aschmoneit, Katharina Kocher, Martin Siegemund, et al.
Mabs|September 26, 2018
Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activityFabian Richter, Kirstin A Zettlitz, Oliver Seifert, et al.
Medicina (Kaunas, Lithuania)|September 27, 2025
Genital Lichen Sclerosus-The Role of the Vulvar MicrobiomeSandra Jerkovic Gulin, Olivia Almlöf, Oliver Seifert, et al.
Molecular Cancer Therapeutics|September 15, 2017
Superior Properties of Fc-comprising scTRAIL Fusion ProteinsMeike Hutt, Lisa Marquardt, Oliver Seifert, et al.
Experimental Dermatology|April 19, 2017
Expression of low-density lipoprotein-related receptors 5 and 6 (LRP5/6) in psoriasis skinAlbert Duvetorp, Renate Slind Olsen, Helena Nyström, et al.
Scientific Reports|May 19, 2018
IgG-single-chain TRAIL fusion proteins for tumour therapyMartin Siegemund, Felix Schneider, Meike Hutt, et al.
Protein Engineering, Design & Selection : PEDS|September 19, 2012
The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificityOliver Seifert, Aline Plappert, Nadine Heidel, et al.
Cell Death and Differentiation|February 22, 2020
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonismVesna Vetma, Cristiano Guttà, Nathalie Peters, et al.
Molecular Therapy. Oncology|January 19, 2026
Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFRMartin A Boos, Oliver Seifert, Stefanie Sawall, et al.
Molecular Cancer Therapeutics|May 21, 2020
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3Alexander Rau, Wolfgang S Lieb, Oliver Seifert, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Oncoimmunology|January 27, 2022
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)Nadine Aschmoneit, Katharina Kocher, Martin Siegemund, et al.
Mabs|September 26, 2018
Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activityFabian Richter, Kirstin A Zettlitz, Oliver Seifert, et al.
Medicina (Kaunas, Lithuania)|September 27, 2025
Genital Lichen Sclerosus-The Role of the Vulvar MicrobiomeSandra Jerkovic Gulin, Olivia Almlöf, Oliver Seifert, et al.
Molecular Cancer Therapeutics|September 15, 2017
Superior Properties of Fc-comprising scTRAIL Fusion ProteinsMeike Hutt, Lisa Marquardt, Oliver Seifert, et al.
Experimental Dermatology|April 19, 2017
Expression of low-density lipoprotein-related receptors 5 and 6 (LRP5/6) in psoriasis skinAlbert Duvetorp, Renate Slind Olsen, Helena Nyström, et al.
Scientific Reports|May 19, 2018
IgG-single-chain TRAIL fusion proteins for tumour therapyMartin Siegemund, Felix Schneider, Meike Hutt, et al.
Protein Engineering, Design & Selection : PEDS|September 19, 2012
The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificityOliver Seifert, Aline Plappert, Nadine Heidel, et al.
Cell Death and Differentiation|February 22, 2020
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonismVesna Vetma, Cristiano Guttà, Nathalie Peters, et al.
Molecular Therapy. Oncology|January 19, 2026
Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFRMartin A Boos, Oliver Seifert, Stefanie Sawall, et al.
Molecular Cancer Therapeutics|May 21, 2020
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3Alexander Rau, Wolfgang S Lieb, Oliver Seifert, et al.
Pageof 9